Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Posters FSGS

Efficacy and Safety of ACE Inhibitors and ARB Therapies in Primary FSGS Treatment: A Systematic Review and Meta-analysis

Learn More
Posters

The Dual ETAR/AT1R Blocker Sparsentan Prevents Noise-Induced Hearing Loss in Alport Mice

Learn More
Posters

The Dual ETAR/AT1R Blocker Sparsentan Attenuates Noise-Induced Hearing Loss in Alport Mice

Learn More
Posters

Characteristics Of Patients Participating In A Study Of Homocystinuria Due To Cystathionine Beta-synthase Deficiency

Learn More
Posters

Homocysteine Is Negatively Correlated With Cognition In Homocystinuria Due To Cystathionine Beta-synthase Deficiency

Learn More
Posters

Comorbid Diagnoses, Medications, and Healthcare Provider Types among Patients Diagnosed

Learn More
Posters FSGS

No Impact of Newly Initiated Immunosuppressive Therapy Observed on Long-Term Antiproteinuric Effect of Sparsentan in Focal Segmental Glomerulosclerosis: Interim 84-Week Analysis of the DUET Trial

Learn More
Posters FSGS

Sparsentan for Treatment of Patients With Focal Segmental Glomerulosclerosis (FSGS): Design of the Phase 3 DUPLEX Study

Learn More
Posters FSGS

Impact of Sparsentan on Quality of Life (QoL) in Focal Segmental Glomerulosclerosis (FSGS) Patients in DUET: an Interim Analysis

Learn More
Posters

Comparison of the Estimated Prevalence of Diagnosed Homocystinuria and Phenylketonuria in the United States

Learn More
Posters

Claims-Based Analysis of Homocysteine Testing, Elevated Homocysteine Levels,

Learn More
Posters IgAN

PROTECT in Immunoglobulin A Nephropathy (IgAN): Study Design of a Phase 3, Randomized Double-blind, International, Active-controlled Study of the Efficacy and Safety of Sparsentan

Learn More
Posters FSGS

Newly Administered Immunosuppressive Therapy (IST) Has No Impact on Long-term Antiproteinuric Effect of Sparsentan (SPAR), a Dual Angiotensin and Endothelin Receptor Antagonist, in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS): Interim Analysis of the Phase 2 DUET Trial

Learn More